You are leaving Medscape Education
Cancel Continue
News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point

Specialty: Multispecialty
Allergy & Immunology
Anesthesiology
Business of Medicine
Cardiology
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Medicine
Gastroenterology
General Surgery
Hematology - Oncology
HIV/AIDS
Hospital Medicine
Infectious Diseases
Internal Medicine
Multispecialty
Nephrology
Neurology
Ob/Gyn & Women's Health
Oncology
Ophthalmology
Orthopedics
Pathology & Lab Medicine
Pediatrics
Plastic Surgery
Psychiatry
Public Health
Pulmonary Medicine
Radiology
Rheumatology
Transplantation
Urology
Interprofessional
Shared Decision Making
Nurses
Pharmacists
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      Sunday, September 24, 2023
      News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
       
       

      CPD

      Development of Heart Failure Following Myocardial Infarction: Why Risks Still Remain High

      • Authors: Marc C. Petrie, MD; Deepak Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI
      • CPD Released: 6/15/2023
      • Valid for credit through: 6/15/2024, 11:59 PM EST
      Start Activity

      • Credits Available

        Non-US Physicians - maximum of 0.25 CPD

        You Are Eligible For

        • Letter of Completion

      Target Audience and Goal Statement

      This educational activity is intended for an international audience of non-US OUS cardiologists and primary care providers (PCPs).

      The goal of this activity is for learners to be better able to describe the risk of development of heart failure (HF) following a myocardial infarction (MI).

      Upon completion of this activity, participants will:

      • Have increased knowledge regarding the
        • Comparative risks of patients developing HF post-MI vs developing stent thrombosis
        • Temporal risk profile of post-MI patients developing HF
        • Gaps in management of patients that develop HF post-MI

      Disclosures

      WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

      All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

      Disclosures for additional planners can be found here.

      Faculty

      • Marc C. Petrie, MD

        Professor of Cardiology
        University of Glasgow
        Glasgow, Scotland

        Disclosures

        Marc C. Petrie, MD, has no relevant financial relationships.

      • Deepak Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI

        Director of Mount Sinai Heart
        Dr. Valentin Fuster Professor of Cardiovascular Medicine
        Icahn School of Medicine at Mount Sinai Health System
        New York, New York, United States

        Disclosures

        Deepak Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI, has the following relevant financial relationships:
        Consultant or advisor for: Angiowave; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Broadview Ventures; Cardax; CellProthera; Cereno Scientific; High Enroll; Hims, Inc.; Janssen; Level Ex; McKinsey & Company; Merck; MyoKardia; NirvaMed; Novo Nordisk; PhaseBio Pharmaceuticals, Inc.; PLx Pharma, Inc.; Regado Biosciences; Stasys
        Research funding from: 89Bio; Abbott; Acesion Pharma; Afimmune; Aker Biomarine; Amarin Corporation plc; Amgen, Inc.; AstraZeneca; Bayer; Beren; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol Myers Squibb Company; Cardax; CellProthera; Cereno Scientific; Chiesi Pharmaceuticals, Inc.; CinCor Pharma; Cleerly; CSL Behring; Eisai, Inc.; Ethicon; Faraday Pharmaceuticals; Forest Laboratories, Inc.; Fractyl Laboratories, Inc.; Garmin; HLS Therapeutics; Idorsia Pharmaceuticals, Ltd.; Ironwood Pharmaceuticals, Inc.; Ischemix, Inc.; Janssen; Javelin; Lexicon Pharmaceuticals, Inc.; Lilly; Medtronic, Inc.; Merck; Moderna, Inc.; MyoKardia; NirvaMed; Novartis; Novo Nordisk; Owkin; PhaseBio Pharmaceuticals, Inc.; PLx Pharma, Inc.; Recardio Biosciences; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi; Stasys; Synaptic Pharmaceuticals Corporation; The Medicines Company; Youngene Therapeutics
        Contracted researcher for: Abbott; Biotronik; Boston Scientific; CSI; Endotronix; St. Jude Medical; Philips; SpectraWAVE; Svelte; Vascular Solutions, Inc.
        Patent beneficiary of: Sotagliflozin (Lexicon Pharmaceuticals)
        Stock options from: Angiowave; DRS.LINQ
        Owns stock (privately owned) in: High Enroll
        Owns stock (publicly traded) in: Bristol Myers Squibb Company
        Other: Board of Directors for Angiowave; Bristol Myers Squibb Company; DRS.LINQ; High Enroll; TobeSoft. Data Safety Monitoring Committee for Acesion Pharma; Boston Scientific; Contego Medical; Novartis

      Editor

      • Lorena Casadonte, PhD

        Medical Education Director, WebMD Global, LLC

        Disclosures

        Lorena Casadonte, PhD, has no relevant financial relationships.

      Compliance Reviewer

      • Amanda Jett, PharmD, BCACP

        Associate Director, Accreditation and Compliance, Medscape, LLC

        Disclosures

        Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

      Peer Reviewer

      This activity has been peer reviewed and the reviewer has no relevant financial relationships.

      Accreditation Statements

        For Physicians

      • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.25 continuing professional development credits (CPD).

        Contact WebMD Global

      For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

      Instructions for Participation and Credit

      There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

      This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

      Follow these steps to claim a credit certificate for completing this activity:

      1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
      2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

      We encourage you to complete an Activity Evaluation to provide feedback for future programming.

      You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

      *The credit that you receive is based on your user profile.

      < Clinical Advances in Treating Across the Spectrum of Heart Failure
      From Medscape Education
      CPD

      Development of Heart Failure Following Myocardial Infarction: Why Risks Still Remain High

      Authors: Marc C. Petrie, MD; Deepak Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAIFaculty and Disclosures

      CPD Released: 6/15/2023

      Valid for credit through: 6/15/2024, 11:59 PM EST

      processing....

      Transkription in Deutsch

      Download the pdf.

      Download Now

      « Return to: Development of Heart Failure Following Myocardial Infarction: Why Risks Still Remain High
      Download Slides

      PDF Downloads

          Transcript Downloads

          • Print
          Find Us On
          About
          About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
          Membership
          Become a Member About You Professional Information Newsletters & Alerts Market Research
          App
          Medscape
          WebMD Network
          Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
          Editions
          English Deutsch Español Français Português UK
          All material on this website is protected by copyright, Copyright © 1994-2023 by WebMD LLC. This website also contains material copyrighted by 3rd parties.